Grow Opportunity

News Business International
Cronos enters United Kingdom cannabis market

May 7, 2024  By Grow Opportunity Staff


(Globe Newswire) Toronto — Cronos Group Inc. announced that it is expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW® Pharma, a leading distributor of prescribed medicinal cannabis products in the UK.

Cronos will provide high-quality premium cannabis products, which have become synonymous globally with the PEACE NATURALS® brand, to patients in the U.K. through this partnership. The company’s investments in R&D, tissue culture, and its cannabis genetics breeding program have enabled it to expand to Germany and Australia in the past year.

“Supplying the U.K. market, which we think has the potential to grow significantly this year, is another milestone for Cronos as we enter and expand within international markets,” said Mike Gorenstein, chairman, president and CEO of Cronos. “We intend to establish PEACE NATURALS® as a top brand in the U.K., as we have done in Israel and Germany. We will continue to push forward on new market growth opportunities and expand our portfolio of borderless products while growing our European footprint.”

Grow Pharma works with U.K.-based clinics as a wholesaler and pharmacy distributor as well as directly with patients by handling prescriptions and delivering products by mail. Their focus on quality of the supply chain, breadth of their portfolio and delivery of the best service to patients support their strong position as one of the market leaders.

Advertisement

“We’re proud and excited to partner with Cronos and to further expand our offering to U.K. patients with high-quality medical cannabis products,” said Pierre van Weperen, CEO of Grow Pharma. “As demand continues to increase and the expectations for high quality medical products are shifting upwards across the U.K., we’re pleased about this new partnership and to be able to supply PEACE NATURALS® medical cannabis products to patients.”


Print this page

Advertisement

Stories continue below


Related